Alimera Sciences, Inc.(NASDAQ : ALIM)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading ALIM News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.03%||67.51||1.0%||$573.84m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.19%||373.00||2.1%||$318.70m|
|KITE||Kite Pharma, Inc.||3.14%||76.84||18.8%||$216.10m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.83%||119.26||1.6%||$202.32m|
|ESPR||Esperion Therapeutics, Inc.||-3.61%||38.94||18.7%||$166.57m|
|AUPH||Aurinia Pharmaceuticals Inc.||-4.41%||8.02||6.3%||$143.97m|
|CLVS||Clovis Oncology, Inc.||2.61%||70.32||17.5%||$141.44m|
|VRTX||Vertex Pharmaceuticals Incorporated||1.04%||89.98||2.2%||$134.68m|
Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.